Previous 10 | Next 10 |
SHELTON, CT / ACCESSWIRE / February 15, 2022 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, has filed the quarterly report for second quarter of its 2022 fiscal ...
SHELTON, CT / ACCESSWIRE / November 16, 2021 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), has filed its quarterly report for its first quarter o...
Creative Realities (NASDAQ:CREX) +91% industry merger creates powerful new digital signage leader EyePoint Pharmaceuticals EYPT +36% reports positive EYP-1901 data for treatment of wet AMD Bit Brother (NASDAQ:BTB) +20%. Oxbridge Re Holdings OXBR +15% on Q3 earnings. Cue Biophar...
SHELTON, CT / ACCESSWIRE / November 15, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, announced today that it has developed oral gummies formulations of its Pan...
SHELTON, CT / ACCESSWIRE / October 13, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2021 with the Securities and Exchange Commission (SEC) on Tuesday, October 12, 2021. The repo...
Palm Beach, FL –October 11, 2021 – FinancialNewsMedia.com News Commentary – With the arrival of the COVID-19 virus, the antivirals market had all eyes watching the ongoing frenetic rush to find a cure or at least a therapy. That race has not yet abatedȂ...
Protagonist Therapeutics (NASDAQ:PTGX) +89% after FDA removes clinical hold on rusfertide program Flexion Therapeutics (NASDAQ:FLXN) +73% Pacira Therapeutics acquires Flexion Therapeutics for $8.50 per share in cash plus one CVR Adamas Pharmaceuticals (NASDAQ:ADMS) +7...
SHELTON, CT / ACCESSWIRE / October 11, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, announced today that its Pan-Coronavirus COVID-19 Drug Candidate NV-CoV-2...
NanoViricides Provides Update on Its Pan-Coronavirus COVID-19 Drug Development Program at Benzinga Healthcare Small Cap Conference Canada NewsWire SHELTON, Conn. , Oct. 5, 2021 /CNW/ -- NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a leader ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome back, investor! We’re starting off the week with a dive into the biggest pre-market stock movers for Monday! Source: Eric Urquhart/Shutterstock.com We’re seeing a lot of movement from penny sto...
News, Short Squeeze, Breakout and More Instantly...
NV-387, A Broad-Spectrum Antiviral with Strong Activity Against RSV, Influenza A, Coronaviruses, Others SHELTON, CT / ACCESSWIRE / May 20, 2024 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, says that the strong antiv...
NV-387 Advancing to Phase II Clinical Trial for the Treatment of RSV Infection SHELTON, CT / ACCESSWIRE / May 15, 2024 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, reports that it has filed its Quarterly Report on F...